You are creating *** arguments. I didn't say it is easy and cheap. I said that what occurred with MSB is not the reality that most companies go through, but since it's your only experience you are projecting that it will happen to everyone else. Which is BS.
Even if you think Cynata has a slim chance of approval (say 5%), then you need to adjust for the relative size of the market they are targeting (3.3x), then project how long until it would be commercialised (say 4 years conservatively). You can hypothesise this: 'in 4 years Cynata's risk-adjusted market cap should be (1/16.5)th of MSB's present market cap of $4000M.'
CYP market cap = $242M = $1.07/share in 4 years. Current price = $0.23/share. 47% compounded annual return.
edit: who would have thought "5traw m4n" would be moderated
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)